1887

Journal of Medical Microbiology logo

Volume 72, Issue 12

Mixture modelling of serology samples to evaluate anti-pertussis toxin immunoglobulin G titre thresholds for positivity: England 2008–2022 Open Access

Abstract

Antibody testing for evidence of a recent infection by estimating anti-pertussis toxin immunoglobulin G (anti-PT-IgG) titres by enzyme-linked immunosorbent assays is often recommended for those with a cough lasting more than 14 days. Interpreting results varies, with studies recommending different anti-PT-IgG titre thresholds for assigning positivity. In England, early work looking at antibody titre distributions for samples submitted from April 2010 to July 2012 found an optimal threshold of greater than 70 IU ml for good sensitivity, specificity and positive predictive value.

The aim of this study is to use the same mixture modelling technique to determine if the 70 IU ml threshold remains appropriate when assessing data before, during and after the outbreak of pertussis in 2011–2012.

We reviewed titres for all serology-tested samples in England between 1 July 2008 to 30 June 2022. IgG titres were used to calculate the positivity based on the current threshold of 70 IU ml, the median duration of cough for individuals who tested positive and, through mixture modelling, the sensitivity, specificity, positive and negative predictive values (PPV and NPV) of assay thresholds.

Positivity rates increased from 21.7 % prior to the outbreak to 30.3 % during the outbreak and dropped to 25.1 % post-outbreak; similar to estimates from the mixture model of 20.5, 33.3 and 28.7 %, respectively. Although the estimated sensitivity dropped during and after the outbreak when applying the 70 IU ml threshold, the PPV remained high and therefore no change to this threshold is warranted.

Mixture modelling is a useful tool to establish thresholds, but reassessment should also be done when there have been changes to prevalence and/or testing regimes to determine whether there have been any changes in sensitivity, specificity, PPV, and NPV and whether the threshold should be revised.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antibody , IgG titres , pertussis , serology and threshold
© 2023 Crown Copyright
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001774
2023-12-04
2024-04-27
Loading full text...

Full text loading...

/deliver/fulltext/jmm/72/12/jmm001774.html?itemId=/content/journal/jmm/10.1099/jmm.0.001774&mimeType=html&fmt=ahah

References

  1. England PH. Guidelines for the Public Health Management of Pertussis in England 2018
     [Google Scholar]
  2. Baughman AL, Bisgard KM, Edwards KM, Guris D, Decker MD et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 2004; 11:1045–1053 [View Article] [PubMed]
     [Google Scholar]
  3. Xing D, Wirsing von König CH, Newland P, Riffelmann M, Meade BD et al. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. Clin Vaccine Immunol 2009; 16:303–311 [View Article] [PubMed]
     [Google Scholar]
  4. Barkoff A-M, Gröndahl-Yli-Hannuksela K, He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. Pathog Dis 2015; 73:ftv050 [View Article] [PubMed]
     [Google Scholar]
  5. Guiso N, Berbers G, Fry NK, He Q, Riffelmann M et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011; 30:307–312 [View Article] [PubMed]
     [Google Scholar]
  6. Fry NK, Litt DJ, Duncan J, Vaghji L, Warrener L et al. Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay. J Med Microbiol 2013; 62:1281–1289 [View Article] [PubMed]
     [Google Scholar]
  7. England PH. Health Protection Report Weekly Report 2014
     [Google Scholar]
  8. Edmunds M, Mearkle R, Folliard J, Anderson C, Balasegaram S et al. Retrospective cohort study investigating extent of pertussis transmission during a boarding school outbreak, England, December 2017 to June 2018. Euro Surveill 2021; 26:1900736 [View Article] [PubMed]
     [Google Scholar]
  9. Tessier E, Campbell H, Ribeiro S, Andrews N, Stowe J et al. Investigation of a pertussis outbreak and comparison of two acellular booster pertussis vaccines in a junior school in South East England, 2019. Euro Surveill 2021; 26:2000244 [View Article] [PubMed]
     [Google Scholar]
  10. Vyse AJ, Gay NJ, Hesketh LM, Pebody R, Morgan-Capner P et al. Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiol Infect 2006; 134:1303–1312 [View Article] [PubMed]
     [Google Scholar]
  11. Gay NJ. Analysis of serological surveys using mixture models: application to a survey of parvovirus B19. Stat Med 1996; 15:1567–1573 [View Article] [PubMed]
     [Google Scholar]
  12. Vyse AJ, Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adults. Epidemiol Infect 2004; 132:1129–1134 [View Article] [PubMed]
     [Google Scholar]
  13. Kafatos G, Andrews NJ, McConway KJ, Maple PAC, Brown K et al. Is it appropriate to use fixed assay cut-offs for estimating seroprevalence?. Epidemiol Infect 2016; 144:887–895 [View Article] [PubMed]
     [Google Scholar]
  14. Tenny SHM. Prevalence StatPearls; 2023 https://www.ncbi.nlm.nih.gov/books/NBK430867/
  15. Team RC. A Language and Environment for Statistical Computing 2021
     [Google Scholar]
  16. SataCorp Stata Statistical Software: Release 17 2021
     [Google Scholar]
  17. Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R. Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol 2008; 56:45–50 [View Article] [PubMed]
     [Google Scholar]
  18. Baughman AL, Bisgard KM, Lynn F, Meade BD. Mixture model analysis for establishing a diagnostic cut-off point for pertussis antibody levels. Stat Med 2006; 25:2994–3010 [View Article] [PubMed]
     [Google Scholar]
  19. NHS Whooping cough; 2023 https://www.nhs.uk/conditions/whooping-cough
  20. Wirsing von König CH, Gounis D, Laukamp S, Bogaerts H, Schmitt HJ. Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Eur J Clin Microbiol Infect Dis 1999; 18:341–345 [View Article] [PubMed]
     [Google Scholar]
  21. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, Elvers LH, Berbers GA et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000; 38:800–806 [View Article] [PubMed]
     [Google Scholar]
  22. Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL et al. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis 2000; 182:1409–1416 [View Article] [PubMed]
     [Google Scholar]
  23. Tessier E, Campbell H, Ribeiro S, Rai Y, Burton S et al. Impact of the COVID-19 pandemic on Bordetella pertussis infections in England. BMC Public Health 2022; 22:405 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001774
Loading
Mixture modelling of Bordetella pertussis serology samples to evaluate anti-pertussis toxin immunoglobulin G titre thresholds for positivity: England 2008–2022
J. Med. Microbiol. 72, 001774 (2024); https://doi.org/10.1099/jmm.0.001774
/content/journal/jmm/10.1099/jmm.0.001774
/content/journal/jmm/10.1099/jmm.0.001774
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error